Your browser doesn't support javascript.
loading
A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Stamatatos, Leonidas; Czartoski, Julie; Wan, Yu-Hsin; Homad, Leah J; Rubin, Vanessa; Glantz, Hayley; Neradilek, Moni; Seydoux, Emilie; Jennewein, Madeleine F; MacCamy, Anna J; Feng, Junli; Mize, Gregory; De Rosa, Stephen C; Finzi, Andrés; Lemos, Maria P; Cohen, Kristen W; Moodie, Zoe; McElrath, M Juliana; McGuire, Andrew T.
Afiliação
  • Stamatatos L; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Czartoski J; Department of Global Health, University of Washington, Seattle, WA, USA.
  • Wan YH; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Homad LJ; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Rubin V; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Glantz H; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Neradilek M; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Seydoux E; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Jennewein MF; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • MacCamy AJ; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Feng J; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Mize G; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • De Rosa SC; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Finzi A; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
  • Lemos MP; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Cohen KW; Centre de Recherche du CHUM, Montréal, QC, Canada.
  • Moodie Z; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
  • McElrath MJ; Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
  • McGuire AT; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
medRxiv ; 2021 Mar 10.
Article em En | MEDLINE | ID: mdl-33758873
ABSTRACT
Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos